Abstract
Autografting with CD34+ cell-selected peripheral blood progenitor cells (PBPC) is often associated with a prolonged recovery time and a higher incidence of infections. The aim of our study was to evaluate whether underlying disease influences hemopoietic recovery and the infectious complications occurring after transplantation. We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC. PBPC were collected after mobilizing chemotherapy plus granulocyte colony-stimulating factor and were processed for selection of CD34+ cells. After selection, a median of 53% CD34+ cells was recovered with a median final purity of 92% with no significant differences between the MM (52% and 92%, respectively) and BC (53% and 89%, respectively) patients. Medians of 4.5 X 106/kg CD34+ cells (BC, 4.4 X 106/kg; MM, 5.4 X 106/kg) and 18 X 104/kg colony-forming units-granulocytemacrophage (BC, 21 X 104/kg; MM, 16 X 104/kg) were reinfused after each HDC. Twenty-six patients (10 MM and 16 BC) underwent tandem autografting, and 10 patients received only 1 autograft because of inadequate collection (5 patients), clinical condition (3 patients), and refusal (2 patients). In the BC patients, the HDC regimen included a high-dose melphalan course followed by an ICE (ifosfamide, carboplatin, and etoposide) course. In the MM patients, the regimen consisted of a course of high-dose melphalan therapy and a course of ICBV (idarubicin, cyclophosphamide [Cytoxan], BCNU, and etoposide) or total body irradiation, etoposide, and Cytoxan. We found a significantly prolonged time for neutrophil recovery to >500/µL in the MM patients (13 days versus 10 days; P <.002), whereas the times for platelet recovery to >20,000/µL in the two groups were not different (13 days versus 12 days; not significant). No late engraftment failures and no toxic deaths were observed. The incidences of extrahematologic toxicity were similar for the two patient groups. All patients received similar anti-infection prophylaxis for 3 months after transplantation. After 12 months of observation, we found a statistically significant higher incidence of bacterial infections in MM patients in both the early (77.8% versus 48.6%; P <.034) and the late (41.1% versus 0%; P <.014) posttransplantation periods, whereas the incidences of fungal infections were similar in the two groups. Viral infections consisted of herpes zoster virus infection in 2 patients of each group, and cytomegalovirus infection was observed in 3 MM patients and no BC patients. Our experience demonstrates a prolonged neutrophil recovery time and higher incidences of bacterial and viral infections in MM patients compared with BC patients. These observations, although limited by the small sample size, suggest that the underlying disease may influence the incidence of infections after CD34+ cell-selected transplantation and should be considered in the planning of appropriate antimicrobial prophylaxis in the autologous transplantation setting.
Similar content being viewed by others
References
Schiller G, Vescio R, Freytes C, et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.Bone Marrow Transplant. 1998;21:141–145.
Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were infused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy.Blood. 2000;95:2234–2239.
Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.Blood. 1999;93:1858–1868.
Antman KH, Rowlings PA, Vaugham PW, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.J Clin Oncol. 1997;15:1870–1897.
Shpall EJ, LeMaistre CF, Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer receiving high-dose chemotherapy.Blood. 1997;90:4313–4320.
Nachbaur D, Fink FM, Nussbaumer W, Gachter A, Krophofer G, Ludescher C. CD34+-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors: a single-centre experience.Bone Marrow Transplant. 1997;20:827–834.
Voso MT, Hohaus S, Moos M, et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content.Br J Haematol. 1999;104:382–391.
Rutella S, Rumi C, Laurenti L, et al. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.Br J Haematol. 2000;108:105–115.
Nishio M, Koizumi K, Endo T, Fujimoto K, Koike T, Sawada K. Diminished T-cell recovery after CD34 selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus infection.Haematologica. 2001;86:667–668.
Lalle M, De Rosa L, Pandolfi A, et al. Immune recovery in breast cancer patients after tandem high-dose chemotherapy rescued by selected CD34+ cells.J Hematother Stem Cell Res. 2002;11:983–986.
Takeshima M, Takamatsu H, Iida M, Mochizuki Y, Okumura H, Yoshida T. Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation.Int J Hematol. 1999;70:193–199.
Goerner M, Wandt H, Schafer-Eckart K, Birkmann J, Denzel T, Gallmeier WM. The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications.J Hematother Stem Cell Res. 1999;8:387–391.
Miyamoto T, Gondo H, Miyoshi Y, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma.Br J Haematol. 1998;100;348–350.
Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.Blood. 1999;94:4029–4035.
Schiller GJ, Vescio R, Berenson J. Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells [letter].Blood. 2000;96:1194.
Nachbaur D, Kropshoffer G, Feichtinger H, Allerberger F, Niederweiser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBPCT): treatment with paramomycin, azithromycin and recombinant human interleukin-2.Bone Marrow Transplant. 1997;19:1261–1263.
Crippa FL, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood progenitor cell transplantation.Biol Blood Marrow Transplant. 2002;8:281–289.
Friedman J, Lazarus HM, Koc ON. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation.Bone Marrow Transplant. 2000;26:831–836.
Peggs KS, Ings SJ, Kotlaridis PD, et al. Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring [letter].Blood. 2000;96:369–370.
Maeda S, Kagami Y, Ogura M, et al. CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.Int J Hematol. 2001;74:214–221.
Berenson RJ, Bensinger WI, Kalamasz DF, et al. Transplantation of stem cells enriched by immunoadsorption.Prog Clin Biol Res. 1992;377:449–457.
Rowley SD, Loken M, Radich J, et al. Isolation of CD34+ cells from blood stem cells components using the Baxter Isolex system.Bone Marrow Transplant. 1997;21:1253–1262.
Ljungman P, De Bock R, Cordonnier C, et al. Practices of cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.Bone Marrow Transplant. 1993;12:399–403.
Blystad AK, Holte H, Kvaloy S, Smeland E, Delabie J, Kvalheim G. High-dose therapy in patients with Hodgkin’s disease: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells.Bone Marrow Transplant. 2001;28:849–857.
Martin S, Voso MT, Hohaus S, Ho AD, Haas R. The time to hematopoietic reconstitution following high-dose therapy in cancer patients is related to the number of CD34+ cells transplanted, diagnosis and type of conditioning regimen.Ann Hematol. 1998;77(suppl 1):A5.
Sezer O, Eucker J, Bauhuis C, Schweigert M, Luftner D, Kalus U. Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer after high- dose chemotherapy with autologous peripheral stem cell transplantation.Ann Hematol. 2000;79:627–630.
Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors.Bone Marrow Transplant. 2001;27:525–529.
Barton TD, Collis T, Stadtmauer EA, Schuster MG. Infectious complications after autologous bone marrow transplantation for treatment of breast cancer.Clin Infect Dis. 2001;32:391–395.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
De Rosa, L., Anghel, G., Pandolfi, A. et al. Hemopoietic Recovery and Infectious Complications in Breast Cancer and Multiple Myeloma after Autologous CD34+ Cell-Selected Peripheral Blood Progenitor Cell Transplantation. Int J Hematol 79, 85–91 (2004). https://doi.org/10.1007/BF02983539
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983539